KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
Publication year
2011Source
British Journal of Cancer, 104, 6, (2011), pp. 1020-6ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Pathology
Health Evidence
IQ Healthcare
Rehabilitation
Medical Oncology
Former Organization
Epidemiology, Biostatistics & HTA
Journal title
British Journal of Cancer
Volume
vol. 104
Issue
iss. 6
Page start
p. 1020
Page end
p. 6
Subject
NCEBP 2: Evaluation of complex medical interventions; NCEBP 6: Quality of nursing and allied health care; ONCOL 3: Translational research; ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathologyAbstract
BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation analysis is usually performed on primary tumour tissue because metastatic tissue is often not available. However, controversial data are available on the concordance of test results between primary tumours and corresponding metastases. We assessed the concordance of KRAS mutation status in a study of 305 primary colorectal tumours and their corresponding liver metastases. METHODS: Patients with histologically confirmed CRC who underwent surgical resection of the primary tumour and biopsy or surgical resection of the corresponding liver metastasis were included. KRAS mutation analysis was performed for codons 12 and 13. RESULTS: KRAS mutation was detected in 108 out of 305 primary tumours (35.4%). In 11 cases (3.6%), we found a discordance between primary tumour and metastasis: 5 primary tumours had a KRAS mutation with a wild-type metastasis, 1 primary tumour was wild type with a KRAS mutation in the metastasis, and in 5 cases the primary tumour and the metastasis had a different KRAS mutation. CONCLUSION: We observed a high concordance of KRAS mutation status of 96.4% (95% CI 93.6-98.2%) between primary colorectal tumours and their corresponding liver metastases. In only six patients (2.0%; 95% CI 0.7-4.2%), the discordance was clinically relevant. In this largest and most homogenous study to date, we conclude that both primary tumours and liver metastases can be used for KRAS mutation analysis.
This item appears in the following Collection(s)
- Academic publications [245400]
- Electronic publications [132943]
- Faculty of Medical Sciences [93207]
- Open Access publications [106464]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.